TICKERNERD
Menu
NDRANDRAHealthcare · Diagnostics & Research

NDRA Stock Forecast: ENDRA Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$4.56
+1.56% on the day

The 1 Wall Street analysts covering ENDRA Life Sciences, Inc. hold a median 12-month price target of $25 — +448.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$6.7M
Ticker Nerd rank
37 / 100
Median analyst target
$25
Analysts covering
1
Revenue$0.0
Operating income−$2.2M
Net income−$1.3M
Free cash flow−$1.1M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.6%
1M
−6.2%
YTD
+0.7%
1Y
+4.0%
From 52W high
−43.8%
From 52W low
+39.9%
$3.26
$8.12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NDRA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ENDRA Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Growth
68
Revisions
68
Momentum
50
Accruals
48
Issuance
39
Volatility
13
Quality
9
Value
4

Size (95): Smaller than most of the companies we track.

Value (4): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NDRA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NDRA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26NDRAHigh $25Median $25Low $25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $25Median $25High $25

The green dot is the last close — the median target sits +448.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 June 2026Ascendiant CapitalMaintainsBuy—
1 June 2026Ascendiant CapitalMaintainsBuy$27 → $25
8 Dec 2025Ascendiant CapitalMaintainsBuy—
22 Sept 2025Ascendiant CapitalMaintainsBuy—
30 May 2025Ascendiant CapitalMaintainsBuy—
21 Apr 2025Ascendiant CapitalMaintainsBuy—
7 June 2024Ascendiant CapitalMaintainsBuy—
31 Mar 2023HC Wainwright & Co.ReiteratesBuy—
7 Apr 2022HC Wainwright & Co.MaintainsBuy$6.00 → $5.00
15 July 2019H.C. WainwrightInitiatesBuy—
15 July 2019HC Wainwright & Co.InitiatesBuy—
20 May 2019Lake StreetInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NDRA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NDRA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, ENDRA Life Sciences, Inc. returned +4.0% against +19.6% for the S&P 500, dividends included.

NDRA vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Oct 25Jan 26Apr 26Jul 26NDRAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NDRA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

ENDRA Life Sciences, Inc. (NDRA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 72% of US stocks

Price / sales
—
Price / book
3.1×

Cheaper than 34% of US stocks

EV / EBITDA
−0.8×

Cheaper than 65% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−152.0%

Higher than 9% of US stocks

Return on assets
−77.3%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ENDRA Life Sciences, Inc. (NDRA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ENDRA Life Sciences, Inc. has a market value of $6.7M and an enterprise value of $5.4M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$7.3M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$8.0M, after $0.0 of capital spending.

  • Shares outstanding: 1.2M.

  • Trailing P/E: 0.2×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • ENDRA Life Sciences, Inc. employs 9 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

NDRA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
NDRAENDRA Life Sciences, Inc.$6.7M
37
XWELXWELL, Inc.$8.8M
39
ISPCiSpecimen, Inc.$4.3M
23
MBAICheck-Cap Ltd.$10.9M
7
ADVBAdvanced Biomed, Inc.$13.4M
16
BIAFbioAffinity Technologies, Inc.$3.2M
16
PRPOPrecipio, Inc.$53.3M
52

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ENDRA Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NDRA news & analysis

ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Business Wire · 17 Aug 2026neutral

ENDRA Life Sciences reported financial results for the quarter ended June 30, 2026, and provided a business update. The company also noted that on June 25, 2026, it entered into a definitive merger agreement with ASP Isotopes Inc. and Noble Africa LLC.

Why it matters — NDRA watchers would care because the update covers the company's latest quarterly financial results and its announced merger agreement, both key developments for the company's outlook.

ASP Isotopes Issues Letter to Shareholders

GlobeNewsWire · 4 Aug 2026neutral

ASP Isotopes Inc. issued a shareholder letter from Executive Chairman and CEO Paul Mann ahead of its Q2 2026 results, reporting that all business units are progressing, group revenues are increasing, and three units are expected to contribute to profitability in the near term. The letter noted its global PET Labs group grew organic revenue by over 50% in first-half 2026 compared with first-half 2025.

Why it matters — While this news concerns a separate company (ASP Isotopes) rather than ENDRA Life Sciences, an NDRA watcher may find it relevant as a shareholder communication from a peer in the broader life-sciences and advanced-materials sector.

FAQ

Frequently asked questions about NDRA stock

What is the NDRA stock price forecast for 2026-2027?

The 1 Wall Street analysts covering ENDRA Life Sciences, Inc. have a median 12-month price target of $25, with estimates ranging from $25 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NDRA stock a buy right now?

Of the 1 analysts covering ENDRA Life Sciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ENDRA Life Sciences, Inc. 37 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NDRA?

As at 22 Aug 2026, ENDRA Life Sciences, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

Will NDRA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +448.2% from the last close, and Ticker Nerd's factor model ranks ENDRA Life Sciences, Inc. 37 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NDRA stock forecast for 2030?

No analyst covering ENDRA Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NDRA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $25 over the next 12 months.

How has NDRA stock performed over the past year?

ENDRA Life Sciences, Inc. returned +4.0% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ENDRA Life Sciences, Inc. do?

Endra Life Sciences Inc. is a health technology company dedicated to developing meaningful innovations in the medical imaging sector.

What is the latest news on NDRA?

The most recent item we track (Business Wire, 17 Aug 2026): "ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update". ENDRA Life Sciences reported financial results for the quarter ended June 30, 2026, and provided a business update. The company also noted that on June 25, 2026, it entered into a definitive merger agreement with ASP Isotopes Inc. and Noble Africa LLC.

Company

About ENDRA Life Sciences, Inc.

Endra Life Sciences Inc. is a health technology company dedicated to developing meaningful innovations in the medical imaging sector. The company's primary focus is the advancement and commercialization of its proprietary Thermo Acoustic Enhanced Ultrasound (TAEUS) platform, which aims to provide more effective imaging compared to traditional ultrasound. Endra seeks to improve early diagnosis and treatment monitoring by offering clinicians additional insights into liver fat quantification—an essential factor in detecting and managing non-alcoholic fatty liver disease (NAFLD). Operating in the global healthcare industry, Endra Life Sciences addresses significant diagnostic challenges by integrating cutting-edge technology into routine medical practices. The TAEUS platform stands out for its ability to enhance existing ultrasound systems, thereby facilitating cost-effective and non-invasive assessments of metabolic diseases. Endra Life Sciences plays a pivotal role in the ongoing shift towards more precise and accessible healthcare solutions. By bridging the gap between advanced imaging and everyday clinical use, the company contributes to the broader efforts of improving patient outcomes and reducing healthcare costs.

CEO Mr. Alexander Y. Tokman · 9 employees · United States · https://endrainc.com